DOCSLIB.ORG

Narcotic Drugs Stupefiants Estupefacientes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

ElINCB/1992121Supp.11 INTERNATIONAL NARCOTICS CONTROL BOARD - VIENNA SUPPLEMENT No. 11 TO NARCOTIC DRUGS ESTIMATED WORLD REQUIREMENTS FOR 1993 STATISTICS FOR 1991 ESTIMATES UPDATED AS OF 30 NOVEMBER 1993 ORGANE INTERNATIONAL DE CONTROLE DES STUPEFIANTS - VIENNE SUPPLEMENT N° 11 , A STUPEFIANTS EVALUATIONS DES BESOINS DU MONDE POUR 1993 STATISTIQUES POUR 1991 EVALUATIONS A JOUR AU 30 NOVEMBRE 1993 JUNTA INTERNACIONAL DE FISCALlZACION DE ESTUPEFACIENTES - VIENA SUPLEMENTO N.o 11 A ESTUPEFACIENTES PREVISIONES DE LAS NECESIDADES MUNDIALES PARA 1993 ESTADISTICAS PARA 1991 PREVISIONES ACTUALlZADAS AL 30 DE NOVIEMBRE DE 1993 ~It.~~ ~ -.,.~'JR UNITED NATIONS - NATIONS UNIES - NACIONES UNIDAS 1993 The updating of Table A is carried out by means of 12 monthly supplements. In order to facilitate the task of the exporting countries, the 12 supplements now report all the totals of the estimates and not only the amended data. In this way, each supplement cancels and replaces the published table in its entirety. In order to accelerate the transmission of the supplements to the competent national authorities, the 12 supplements will appear in English. Reading of these 12 supplements in French and Spanish may be facilitated by consulting the indexes of countries and territories and of narcotic drugs appearing in the annual publication. La mise ajour du tableau A s'effectue au moyen de douze supplements mensuels. Afin de faciliter la tache des pays exportateurs, les douze supplements contiennent tous les totaux des evaluations et non pas seulement les chiffres qui ont ete modifies. De celle maniere, chaque supplement annule et rem place entierement le tableau publie. En vue d'accelerer la communication des supplements aux autorites competentes, les douze supplements seront publies en anglais. La lecture en franvais et en espagnol de ces douze supplements pourra etre facilitee par la consultation des index des pays et territoires et des stupefiants de la publication annuelle. La actualizaci6n del cuadro A se efectua mediante doce suplementos mensuales. Para facilitar la tarea de los paises exportadores, en esos doce suplementos figuran todos los totales de las previsiones y no s610 las cifras que se han modificado. De este modo, cada suplemento anula y sustituye por completo el cuadro publicado. Con el fin de acelerar la comunicaci6n de los suplementos alas autoridades nacionales competentes,los doce suplementos aparecen en ingles. La lectura de estos doce suplementos en espafiol y en frances se vera facilitada si se consultan los indices de paises y territorios que figuran en la publicaci6n anual. E/INCB/1992/2/Supp.11 30.11.1993 UNITED NATIONS PUBLICATION ISSN 1013-8250 ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN 1993 TOTAL OF ESTIMATES IN GRAMS PETHIDINE 68 AFGHANISTAN ANTIGUA AND BARBUDA ------------------------- ------------------------ CODEINE 189 540 COCAINE 24 ETHYLMORPHINE 1 060 CODEINE 600 FENTANYL 1 FENTANYL 2 METHADONE 50 MORPHINE 12 MORPHINE 500 PETHIDINE 600 OPIUM 8 000 PETHIDINE 10 000 ARGENTINA ------------------------ ALBANIA 3-MONOACETYLMORPHINE 1 ------------------------ ALFENTANIL 400 COCAINE 500 CANNABIS 10 CODEINE 40 000 CANNABIS RESIN 30 ETHYLMORPHINE 500 COCA LEAF 100 FENTANYL 7 COCAINE 2 000 PETHIDINE 5 000 CODEINE 400 000 CONC. OF POPPY STRAW 500 000 ALGERIA DEXTROPROPOXYPHENE 2000 000 ------------------------ DIHYDROCODEINE 80 000 ALFENTANIL 14 DIPHENOXYLATE 5 000 CODEINE 300 000 ECGONINE 1 DEXTROMORAMIDE 650 ECGONINE BENZOYLESTER 1 FENTANYL 20 ECGONINE CYNNAMOYLMETHYLESTER 1 MORPHINE 300 ECGONINE METHYLESTER 1 PETHIDINE 4 000 ETHYLMORPHINE 60 000 PHENOPERIDINE 350 FENTANYL 631 PHOLCODINE 200 000 HEROIN 10 HYDROCODONE 60 000 ANDORRA METHADONE 10 ------------------------ MORPHINE 430 000 ALFENTANIL 4 OPIUM 10 000 COCAINE 10 OXYCODONE 10 000 CODEINE 20 PETHIDINE 100 000 DEXTROMORAMIDE 10 PHOLCODINE 60 010 ETHYLMORPHINE 5 SUFENTANIL 100 FENTANYL 3 THEBAINE 150 001 METHADONE 15 MORPHINE 110 OPIUM 5 ARMENIA PETHIDINE 200 ------------------------ PHENOPERIDINE 14 TILIDINE 20 See RUSSIAN FEDERATION ANGOLA ------------------------ ARUBA CODEINE 7 620 ------------------------ DEXTROMORAMIDE 1 BEZITRAMIDE 3 FENTANYL 15 COCAINE 29 MORPHINE 30 CODEINE 35 PETHIDINE 365 DEXTROMORAMIDE 1 FENTANYL 1 ANGUILLA HYDROCODONE 1 ------------------------ METHADONE 7 COCAINE 3 MORPHINE 171 CODEINE 4 OPIUM 549 DIHYDROCODEINE 14 OXYCODONE 33 FENTANYL 2 PETHIDINE 1 180 MORPHINE 4 PAGE 2 TOTAL OF ESTIMATES IN GRAMS ASCENSION ISLAND THEBAINE 1 000 ------------------------ FENTANYL 3 AZERBAIJAN MORPHINE 13 ------------------------ PETHIDINE 26 See RUSSIAN FEDERATION AUSTRALIA ------------------------ ALFENTANIL 20 BAHAMAS ANILERIDINE 150 000 ------------------------ CANNABIS 60 CANNABIS 35 COCAINE 16 342 COCAINE 60 CODEINE 8700 000 CODEINE 1 800 CONC. OF POppy STRAW 60970 000 DEXTROPROPOXYPHENE 4 000 DEXTROMORAMIDE 6 582 FENTANYL 1 DEXTROPROPOXYPHENE 1438 000 HYDROCODONE 300 DIFENOXIN 10 MORPHINE 300 DIHYDROCODEINE 200 000 OPIUM 20 DIPHENOXYLATE 120 680 OXYCODONE 750 ETHYLMORPHINE 13 145 PETHIDINE 9 000 ETORPHINE 5 FENTANYL 650 BAHRAIN HEROIN 10 ------------------------ HYDROCODONE 29 211 3-METHYLFENTANYL 1 HYDROMORPHONE 10 COCAINE 211 METHADONE 285 904 CODEINE 1 015 MORPHINE 9908 000 ECGONINE BENZOYLESTER 1 MORPHINE-3-B-D-GLUCURONIDE 1 ETORPHINE 2 MORPHINE-6-B-D-GLUCURONIDE 25 FENTANYL 1 NORCODEINE 1 HYDROMORPHONE 1 NORMETHADONE 1 010 LEVORPHANOL 1 NORMORPHINE 1 MORPHINE 547 OPIUM 52 142 NORCODEINE 1 OXYCODONE 265 752 OXYCODONE 1 OXYMORPHONE 5 000 OXYMORPHONE 1 PETHIDINE 768 674 PETHIDINE 5 000 PETHIDINE INT.-A 235 000 PHENOPERIDINE 2 PHENOPERIDINE 228 PHOLCODINE 541 618 BANGLADESH SUFENTANIL 10 ------------------------ THEBAINE 1932 000 CODEINE 10 650 TILIDINE 50 000 FENTANYL 10 PETHIDINE 151 380 AUSTRIA PHOLCODINE 140 000 ------------------------ ALFENTANIL 379 BARBADOS ALPHAPRODINE 1 ------------------------ COCAINE 2 868 COCAINE 138 CODEINE 182 846 CODEINE 23 000 DEXTROPROPOXYPHENE 224 082 DIHYDROCODEINE 356 DIHYDROCODEINE 210 347 FENTANYL 1 ETHYLMORPHINE 1 578 HYDROCODONE 111 ETORPHINE 10 METHADONE 11 FENTANYL 252 MORPHINE 466 HYDROCODONE 100 OXYCODONE 49 HYDROMORPHONE 200 PETHIDINE 2 455 METHADONE 54 520 METOPON 1 BELARUS MORPHINE 144 656 ------------------------ MORPHINE-6-GLUCURONIDE 85 NICOCODINE 24 130 See RUSSIAN FEDERATION NICOMORPHINE 13 119 OPIUM 19 187 BELGIUM PETHIDINE 76 719 ------------------------ PIRITRAMIDE 8 470 3-MONOACETYLMORPHINE 1 SUFENTANIL 153 6-MONOACETYLMORPHINE 3 ACETYLDIHYDROCODEINE 34 086 ALFENTANIL 40 000 TOTAL OF ESTIMATES IN GRAMS PAGE 3 BEZITRAMIDE 2 729 METHADONE 400 CANNABIS 98 MORPHINE 1 500 COCA LEAF 49 218 OPIUM 100 COCAINE 145 774 OXYCODONE 200 CODEINE 3206 000 OXYMORPHONE 1 CONC. OF POPPY STRAW 2600 000 PETHIDINE 3 000 DEXTROMORAMIDE 47 052 DEXTROPROPOXYPHENE 380 487 BHUTAN DIETHYLTHIAMBUTENE 20 DIFENOXIN 10 CODEINE 3 700 DIHYDROCODEINE 180 440 DEXTROPROPOXYPHENE 450 DIPHENOXYLATE 450 000 MORPHINE 75 DIPIPANONE 60 PETHIDINE 435 ECGONINE BENZOYLESTER 2 ECGONINE METHYLESTER 2 BOLIVIA ETHYLMORPHINE 222 977 ETORPHINE 20 ALFENTANIL 10 ETOXERIDINE 20 COCAINE 25 FENTANYL 17 000 CODEINE 15 170 HEROIN 1 000 DEXTROPROPOXYPHENE 140 000 HYDROCODONE 22 790 DIHYDROCODEINE 2 010 HYDROMORPHONE 1 179 FENTANYL 35 ISOMETHADONE 20 METHADONE 300 LEVOMORAMIDE 910 PETHIDINE 6 000 LEVORPHANOL 20 METHADONE 64 271 BOSNIA AND HERZEGOVINA MORPHINE 3075 000 NICOMORPHINE 20 COCAINE 1 000 NORCODEINE 2 CODEINE 900 000 NORMETHADONE 198 FENTANYL 100 NORMORPHINE 2 METHADONE 1 000 OPIUM 100 000 MORPHINE 1 500 OXYCODONE 3 390 PETHIDINE 3 000 PETHIDINE 44 438 PETHIDINE INT.-B 20 BOTSWANA PHENAZOCINE 20 PHENOPERIDINE 10 CODEINE 432 PHOLCODINE 254 142 DIHYDROCODEINE 1 875 RACEMETHORPHAN 20 DIPIPANONE 25 SUFENTANIL 1 000 FENTANYL 6 THE BACON 42 485 METHADONE 6 THEBAINE 198 486 MORPHINE 1 110 TILIDINE 1604 000 PETHIDINE 6 000 SUFENTANIL 6 BELIZE TILIDINE 125 COCAINE 200 BRAZIL CODEINE 1 500 MORPHINE 50 CODEINE 600 000 PETHIDINE 1 500 DEXTROPROPOXYPHENE 3 000 DIPHENOXYLATE 229 094 BENIN FENTANYL 837 MORPHINE 1882 000 MORPHINE 10 OPIUM 1020 000 OPIUM 1 000 PETHIDINE 500 000 PETHIDINE 1 000 BRITISH VIRGIN ISLANDS BERMUDA CODEINE 600 ALFENTANIL 4 DIHYDROCODEINE 200 COCAINE 200 DIPHENOXYLATE 15 CODEINE 2 000 PETHIDINE 550 DEXTROMORAMIDE 15 DIHYDROCODEINE 1 000 BRUNEI DARUSSALAM ETORPHINE 5 FENTANYL 1 ALFENTANIL 2 CANNABIS 20 COCAINE 2 PAGE 4 TOTAL OF ESTIMATES IN GRAMS CODEINE 100 CANADA ETORPHINE 2 ------------------------ FENTANYL 2 ALFENTANIL 841 HEROIN 2 ALPHAPRODINE 450 METHADONE 2 ANILERIDINE 114 927 MORPHINE 187 COCA LEAF 2 500 OPIUM 60 COCAINE 39 500 PETHIDINE 1 709 CODEINE 16669 000 DEXTROPROPOXYPHENE 1275 000 BULGARIA DIFENOXIN 1 ------------------------ DIHYDROCODEINE 1 ALFENTANIL 50 DIPHENOXYLATE 35 645 COCAINE 37 746 ECGONINE 5 CODEINE 9414 000 ETHYLMORPHINE 100 DEXTROMORAMIDE 70 ETORPHINE 4 DIHYDROCODEINE 200 FENTANYL 1 013 DIPHENOXYLATE 31 050 HEROIN 2 800 DIPIPANONE 1 HYDROCODONE 84 021 ETHYLMORPHINE 332 007 HYDROMORPHONE 91 640 FENTANYL 313 LEVORPHANOL 1 619 HEROIN 2 METHADONE 65 614 METHADONE 150 METHYLCODEINE 2 MORPHINE 507 652 MORPHINE 942 723 OPIUM 1100 000 MORPHINE-6-GLUCURONIDE 1 PETHIDINE 167 003 NORCODEINE 1 PIRITRAMIDE 8 393 NORMETHADONE 30 520 SUFENTANIL 2 NORMORPHINE 1 TILIDINE 65 636 OPIUM 91 157 OXYCODONE 129 608 BURKINA FASO OXYMORPHONE 245 ------------------------ PETHIDINE 938 478 DEXTROMORAMIDE 10 PETHIDINE INT.-B 2 FENTANYL 3 SUFENTANIL 45 PETHIDINE 357 THEBAINE 1 PHENOPERIDINE 2 CAPE VERDE BURUNDI ------------------------ ------------------------ CODEINE 118 CODEINE 12 000 MORPHINE 7 DEXTROMORAMIDE 1
Recommended publications
  • INVESTIGATION of NATURAL PRODUCT SCAFFOLDS for the DEVELOPMENT of OPIOID RECEPTOR LIGANDS by Katherine M

    INVESTIGATION of NATURAL PRODUCT SCAFFOLDS for the DEVELOPMENT of OPIOID RECEPTOR LIGANDS by Katherine M

    INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS By Katherine M. Prevatt-Smith Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. _________________________________ Chairperson: Dr. Thomas E. Prisinzano _________________________________ Dr. Brian S. J. Blagg _________________________________ Dr. Michael F. Rafferty _________________________________ Dr. Paul R. Hanson _________________________________ Dr. Susan M. Lunte Date Defended: July 18, 2012 The Dissertation Committee for Katherine M. Prevatt-Smith certifies that this is the approved version of the following dissertation: INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS _________________________________ Chairperson: Dr. Thomas E. Prisinzano Date approved: July 18, 2012 ii ABSTRACT Kappa opioid (KOP) receptors have been suggested as an alternative target to the mu opioid (MOP) receptor for the treatment of pain because KOP activation is associated with fewer negative side-effects (respiratory depression, constipation, tolerance, and dependence). The KOP receptor has also been implicated in several abuse-related effects in the central nervous system (CNS). KOP ligands have been investigated as pharmacotherapies for drug abuse; KOP agonists have been shown to modulate dopamine concentrations in the CNS as well as attenuate the self-administration of cocaine in a variety of species, and KOP antagonists have potential in the treatment of relapse. One drawback of current opioid ligand investigation is that many compounds are based on the morphine scaffold and thus have similar properties, both positive and negative, to the parent molecule. Thus there is increasing need to discover new chemical scaffolds with opioid receptor activity.
  • 2020 Kansas Statutes

    2020 Kansas Statutes

    2020 Kansas Statutes 65-4105. Substances included in schedule I. (a) The controlled substances listed in this section are included in schedule I and the number set forth opposite each drug or substance is the DEA controlled substances code that has been assigned to it. (b) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation: (1) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N- phenylacetamide) 9821 (2) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N- phenylacetamide) 9815 (3) Acetylmethadol 9601 (4) Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide; acryloylfentanyl) 9811 (5) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide) 9551 (6) Allylprodine 9602 (7) Alphacetylmethadol 9603(except levo-alphacetylmethadol also known as levo- alpha-acetylmethadol, levomethadyl acetate or LAAM) (8) Alphameprodine 9604 (9) Alphamethadol 9605 (10) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine) 9814 (11) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N- phenylpropanamide) 9832 (12) Benzethidine 9606 (13) Betacetylmethadol 9607 (14) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N- phenylpropanamide) 9830 (15) Beta-hydroxy-3-methylfentanyl (other
  • ESTIMATED WORLD REQUIREMENTS of NARCOTIC DRUGS in GRAMS for 2019 (As of 10 January 2019 )

    ESTIMATED WORLD REQUIREMENTS of NARCOTIC DRUGS in GRAMS for 2019 (As of 10 January 2019 )

    ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN GRAMS FOR 2019 (as of 10 January 2019 ) Afghanistan Cannabis 50 Codeine 50 000 Cannabis resin 1 Dextropropoxyphene 10 000 Coca leaf 1 Diphenoxylate 5 000 Cocaine 15 Fentanyl 1 Codeine 650 000 Methadone 20 000 Codeine -N-oxide 1 Morphine 8 000 Dextromoramide 1 Pethidine 90 000 Dextropropoxyphene 200 000 Pholcodine 40 000 Difenoxin 1 Albania Dihydrocodeine 1 Cocaine 1 Diphenoxylate 1 Codeine 1 189 000 Dipipanone 1 Fentanyl 300 Ecgonine 2 Heroin 1 Ethylmorphine 1 Methadone 7 000 Etorphine 1 Morphine 7 800 Fentanyl 17 000 Oxycodone 2 000 Heroin 1 Pethidine 2 700 Hydrocodone 10 000 Pholcodine 1 500 Hydromorphone 4 000 Remifentanil 9 Ketobemidone 1 Sufentanil 2 Levorphanol 1 Algeria Methadone 100 000 Alfentanil 350 Morphine 1 550 000 Codeine 2 500 000 Morphine -N-oxide 1 Etorphine 1 Nicomorphine 1 Fentanyl 500 Norcodeine 1 Methadone 4 000 Normethadone 1 Morphine 9 000 Normorphine 1 Oxycodone 4 000 Opium 10 Pethidine 3 000 Oripavine 1 Pholcodine 1 500 000 Oxycodone 60 000 Remifentanil 1 Oxymorphone 1 Sufentanil 30 Pethidine 50 000 Andorra Phenoperidine 1 Cannabis 2 000 Pholcodine 1 Fentanyl 100 Piritramide 1 Methadone 1 000 Remifentanil 20 000 Morphine 500 Sufentanil 10 Oxycodone 2 000 Thebacon 1 Pethidine 500 Thebaine 70 000 Remifentanil 4 Tilidine 1 Angola Armenia Alfentanil 20 Codeine 3 000 Codeine 21 600 Fentanyl 40 Dextromoramide 188 Methadone 13 500 Dextropropoxyphene 200 Morphine 7 500 Dihydrocodeine 500 Thebaine 15 Diphenoxylate 300 Trimeperidine 1 500 Fentanyl 63 Aruba* Methadone 2 000
  • Pain Management After Elective Shoulder Surgery: a Randomized Quantitative Study Comparing Hydromorphone with Piritramide

    Pain Management After Elective Shoulder Surgery: a Randomized Quantitative Study Comparing Hydromorphone with Piritramide

    Case Report J Anest & Inten Care Med Volume 9 Issue 4 - October 2019 Copyright © All rights are reserved by Hermann Prossinger DOI: 10.19080/JAICM.2019.09.555768 Pain Management After Elective Shoulder Surgery: A Randomized Quantitative Study Comparing Hydromorphone With Piritramide Boesmueller S1, Gerstorfer I1, Steiner M1, Prossinger H2*, Fialka C1 and Steltzer H1, 3 1AUVA Meidling, Austria 2Department for Evolutionary Anthropology, University of Vienna, Austria 3Sigmund Freud University, Austria Submission: September 25, 2019; Published: October 11, 2019 *Corresponding author: Hermann Prossinger, Department for Evolutionary Anthropology, Faculty of Life Sciences, University of Vienna, Vienna, Austria Abstract Background: Postoperative pain management plays an important role in elective shoulder surgery. Several methods have been investigated so far. The aim of this randomized quantitative study is to compare two frequently used postoperative pain regimes (hydromorphone versus piritramide) regarding onset and duration after the effectiveness of the single-shot interscalene block has diminished. Methods: All patients who underwent elective shoulder surgery at our institution agreed to participate in this study. Upon admission patients were assigned membership to group A (hydromorphone) or group B (piritramide) according to the patient number (which ensured randomization). Pain assessment was performed using the numeric rating scale (NRS). For statistical analyses the techniques of maximum likelihood (ML) estimation were used. Results: Of the 48 patients aged 18–89 years included in this study, 25 were in group A and 23 in group B. Of these 48, 21 in each group registered pain levels above threshold at least once. Shoulder surgery was performed 45 times in an arthroscopic and 3 times in an open technique.
  • Evidence Review F: Opioids for Pain Relief After Caesarean Birth

    Evidence Review F: Opioids for Pain Relief After Caesarean Birth

    National Institute for Health and Care Excellence FINAL Caesarean birth [F] Opioids for pain relief after caesarean birth NICE guideline NG192 Evidence review March 2021 Final This evidence review was developed by the National Guideline Alliance which is a part of the Royal College of Obstetricians and Gynaecologists FINAL Contents Disclaimer The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian. Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties. NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the Welsh Government, Scottish Government, and Northern Ireland Executive.
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
  • Problems of Drug Dependence 1980 Proceedings of the 42Nd Annual Scientific Meeting the Committee on Problems of Drug Dependence

    Problems of Drug Dependence 1980 Proceedings of the 42Nd Annual Scientific Meeting the Committee on Problems of Drug Dependence

    National Institute on Drug Abuse MONOGRAPH SERIES Problems of Drug Dependence 1980 Proceedings of the 42nd Annual Scientific Meeting The Committee on Problems of Drug Dependence, Inc. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse, and Mental Health Administration Problems of Drug Dependence, 1980 Proceedings of the 42nd Annual Scientific Meeting, The Committee on Problems of Drug Dependence, Inc. Editor: Louis S. Harris, Ph.D. NIDA Research Monograph 34 February 1981 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse Division of Research 5600 Fishers Lane Rockville, Maryland 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, D.C. 20402 The NIDA Research Monograph series is prepared by the Division of Research of the National Institute on Drug Abuse. Its primary objective is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, integrative research reviews and significant original research. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisory Board Avram Goldstein, M.D. Addiction Research Foundation Palo Alto, California Jerome Jaffe, M.D. College of Physicians and Surgeons Columbia University, New York Reese T. Jones, M.D. Langley Porter Neuropsychiatric Institute University of California San Francisco, California William McGlothlin, Ph.D. Deportment of Psychology, UCLA Los Angeles, California Jack Mendelson, M.D. Alcohol and Drug Abuse Research Center Harvard Medical School McLean Hospital Belmont, Massachusetts Helen Nowlis, Ph.D. Office of Drug Education, DHHS Washington, D.C Lee Robins, Ph.D.
  • Chromatography Including Electrophoresis and Other Separation Methods

    Chromatography Including Electrophoresis and Other Separation Methods

    15SIO 06£ i 36 j 6 VOL. 610 NO.2 JUNE 12, 1992 THIS ISSUE COMPLETES VOL. 610 Bibliography Section JOURNAL OF CHROMATOGRAPHY INCLUDING ELECTROPHORESIS AND OTHER SEPARATION METHODS EDITORS U. A. Th. Brinkman (Amsterdam) R. W. Giese (Boston, MA) J. K. Haken (Kensington, N.S.W.) K. Macek (Prague) L. R. Snyder (Orinda, CA) EDITORS. SYMPOSIUM VOLUMES. E. Heftmann (Orinda. CAl. Z. Deyl (Prague) EDITORIAL BOARD D. W. Armstrong (Rollo. MO) W. A. Aue (Holifo,) P. Botek (8.00) A. A. Boulton (Saskatoon) P. W. Cmr (Minneopolis. MN) N. H. C. Cooke (San Ramon. CAl V. A. Davankov (Moscow) Z. Deyl (Progue) S. Dilli (Kl~nsington. N.S.W.) F. Ern! (Basle) M. B. Evans (Hatfield) J. L. Glojcl, (N. Billerico. MA) G. A. Guiochon (Knoxville, TN) P. R. Haddod (Kensington. N.S.W.) I. M. Hais (Hradec Kralove) W. S. Hancock (San FranCISCo. CAl S. Hjerten (Uppsalo) Cs. Horvinh (New Haven. CT) J. F. K. Huber (Vienna) K.·P. Hupe (Woldbronn) T. W. Hutchens (Houston. IX) J. Jonak (B.oo) P. Jandera (Pardubice) B. L. Kmger (B05<on. MA) J. J. Kirkland (Wilmington. DE) E. sz. Kovats (Lausanne) A. J. P. Mortin (Cambridge) L. W. McLoughlin (Chestnut Hill. MA) E. D. Morgan (Keele) J. O. Pearson (KrJlamazoo, MI) H. Poppe (Amsterdam) F. E. Regnier (West Lafayette. IN) P. G. Righetti (Milan) P. Sclloenmakers (Eindhoven) R. Schwarzenbach (Dubendor!) R. E. Shoup (West Lafayette. IN) A. M. Siouf!i (Mo,seille) D. J. Strydom (Boston. MA) N. Tonaka (Kyoto) S. Terabe (Hyogo) K. K. Unger (Mainz) R. Verpoorle (Leiden) Gy.
  • 7.5 Mg/Ml Solution for Injection Piritramide Read All of This Leafle

    7.5 Mg/Ml Solution for Injection Piritramide Read All of This Leafle

    PACKAGE LEAFLET: INFORMATION FOR THE USER Piritramide [MAH] 7.5 mg/ml solution for injection Piritramide Read all of this leaflet carefully before you start using this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet: 1. What Piritramide [MAH] is and what it is used for 2. What you need to know before you are given Piritramide [MAH] 3. How to use Piritramide [MAH] 4. Possible side effects 5. How to store Piritramide [MAH] 6. Contents of the pack and other information 1. WHAT PIRITRAMIDE [MAH] IS AND WHAT IT IS USED FOR Piritramide [MAH] contains the active substance piritramide. It belongs to a group of medicines called opioid analgesics (strong painkillers). Piritramide [MAH] is used to relieve severe to strongest pain. 2. WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN PIRITRAMIDE [MAH] Do not use Piritramide [MAH]: - If you are allergic to piritramide or any of the other ingredients of this medicine (listed in section 6). - If you suffer from severely impaired consciousness from which you cannot be roused even by external stimuli. - If you have problems with breathing (respiratory depression). Warnings and precautions Talk to your doctor or pharmacist before you are given Piritramide [MAH] - If you have suffer from seizures (such as epileptic fits) - If you suffer from alcoholism - If you have head injuries - If you have an increased brain pressure - If you have an enlarged prostate (prostatic hypertrophy) - If you are in shock - If you have a severely slowed heart beat (bradycardia) or irregular heart beat (bradyarrhythmia).
  • Quality Issues in Caring for Older People

    Quality Issues in Caring for Older People

    Doctoral Thesis - Tesis Doctoral Quality issues in caring for older people: • Appropriateness of transition from long-term care facilities to acute hospital care • Potentially inappropriate medication: development of a European list Anna Renom Guiteras Prof. Gabriele Meyer Prof. Ramón Miralles Basseda Martin Luther University Halle-Wittenberg Universitat Autònoma de Barcelona Halle (Saale) & Barcelona, Catalonia University of Witten/Herdecke Spain Witten Germany Programa de doctorat en Medicina Departament de Medicina, Facultat de Medicina Universitat Autònoma de Barcelona Barcelona, 2015 13 Contents 15 1. Introduction • Research context • Background of the research topics • Pesetaio of the ailes 23 2. Summary and discussion of the results 31 3. Conclusions 37 4. References 47 5. Articles • Article 1: Renom-Guiteras A, Uhrenfeldt L, Meyer G, Mann E. Assessment tools for determining appropriateness of admission to acute care of persons transferred from long-term care facilities: a systematic review. BMC Geriatr. 2014;14:80 • Article 2: Renom-Guiteras A, Meyer G, Thürmann PA. The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur J Clin Pharmacol. 2015;71(7):861-75 77 6. Annexes • Annex 1.1 (article 1) - Additional file 1: Studies dealing with assessment tools for determining appropriateness of hospital admissions among residents of LTC facilities. • Annex 1.2 (article 1) - Additional file 2: Characteristics of the assessment tools for determining appropriateness of hospital admissions among residents of LTC facilities. • Annex 2.1 (article 2) - Appendix 1: Complete EU(7)-PIM list • Annex 2.2 (article 2) - Appendix 2: Questionable Potentially Inappropriate Medications (Questionable PIM): results of the Delphi survey.
  • Phencyclidine: an Update

    Phencyclidine: an Update

    Phencyclidine: An Update U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse and Mental Health Administration Phencyclidine: An Update Editor: Doris H. Clouet, Ph.D. Division of Preclinical Research National Institute on Drug Abuse and New York State Division of Substance Abuse Services NIDA Research Monograph 64 1986 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administratlon National Institute on Drug Abuse 5600 Fishers Lane Rockville, Maryland 20657 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 NIDA Research Monographs are prepared by the research divisions of the National lnstitute on Drug Abuse and published by its Office of Science The primary objective of the series is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, and integrative research reviews. its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisors MARTIN W. ADLER, Ph.D. SIDNEY COHEN, M.D. Temple University School of Medicine Los Angeles, California Philadelphia, Pennsylvania SYDNEY ARCHER, Ph.D. MARY L. JACOBSON Rensselaer Polytechnic lnstitute National Federation of Parents for Troy, New York Drug Free Youth RICHARD E. BELLEVILLE, Ph.D. Omaha, Nebraska NB Associates, Health Sciences Rockville, Maryland REESE T. JONES, M.D. KARST J. BESTEMAN Langley Porter Neuropsychiatric lnstitute Alcohol and Drug Problems Association San Francisco, California of North America Washington, D.C. DENISE KANDEL, Ph.D GILBERT J. BOTV N, Ph.D. College of Physicians and Surgeons of Cornell University Medical College Columbia University New York, New York New York, New York JOSEPH V.
  • Misuse and Abuse of Opioid Analgesics – the Role of the Internet

    Misuse and Abuse of Opioid Analgesics – the Role of the Internet

    Misuse and Abuse of Opioid Analgesics – the Role of the Internet H. Siemann, J. Schnell, N. Scherbaum LVR Hospital Essen, Clinic for Dependent Behavior and Addiction Medicine University of Duisburg-Essen, Germany Misuse and Abuse of Opioid Analgesics – the Role of the Internet 09/18/2009 Opioid Analgesics • Prescription Drugs – Tramadol, Tilidine, Codeine, Loperamide – Easy to prescribe • Schedule III Drugs according to the German Narcotics Act (BtmG) – Morphine, Methadone, Fentanyl, Buprenorphine, Oxycodone – Special conditions to be fulfilled for a valid presciption Holger Siemann ([email protected]) 2 Misuse and Abuse of Opioid Analgesics – the Role of the Internet 09/18/2009 Prescription Rate Holger Siemann ([email protected]) 3 Misuse and Abuse of Opioid Analgesics – the Role of the Internet 09/18/2009 Non-Scheduled Opioids • Tramadol – Pain management (post-surgery treatment, injury treatment) • Tilidine + Naloxone (Valoron N®) – Higher analgesic potency – Prevention of parenteral drug abuse by combination with the µ-receptor antagonist Naloxone Holger Siemann ([email protected]) 4 Misuse and Abuse of Opioid Analgesics – the Role of the Internet 09/18/2009 Aim of the Study • To assess the role of the internet regarding the abuse of prescription opioids – Role as a trading platform – Role as an information system Holger Siemann ([email protected]) 5 Misuse and Abuse of Opioid Analgesics – the Role of the Internet 09/18/2009 Methods • Analysis of the first 50 websites provided by the leading search engine Google for